SCHEMBL22096043

SCHEMBL22096043

O=C(O)c1nonc1NCn1nnnc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 3/20 0.68
POLB P06746 3/20 0.51
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
PIN1 Q13526 1/20 0.41
PTGES O14684 1/20 0.38
IDO1 P14902 1/20 0.38
NPC1 O15118 1/20 0.37
ATM Q13315 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.37
XPO1 O14980 1/20 0.37
IP6K1 Q92551 1/20 0.37
IP6K3 Q96PC2 1/20 0.37
IP6K2 Q9UHH9 1/20 0.37
HSD11B1 P28845 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096040 0.90 STAT5B (0.55) STAT5BPOLBHTTL3MBTL1SLC6A2
SCHEMBL22096024 0.87 STAT5B (0.79) STAT5BPOLBHTTSLC6A2SLC6A4
SCHEMBL22096016 0.87 STAT5B (0.81) STAT5BPOLBHTTALDH1A1HSD11B1
SCHEMBL22096023 0.86 STAT5B (0.65) STAT5BPOLBIDO1
SCHEMBL22096022 0.85 STAT5B (0.81) STAT5BPOLBHTTKMT2AALDH1A1
SCHEMBL22096026 0.81 STAT5B (1.00) STAT5BSLC6A2SLC6A4SLC6A3IDO1
SCHEMBL22096045 0.80 STAT5B (0.61) STAT5BALDH1A1SMN1; SMN2
SCHEMBL22096019 0.78 STAT5B (0.62) STAT5BHTTL3MBTL1IDO1KMT2A
SCHEMBL22096042 0.78 STAT5B (0.54) STAT5BPOLBL3MBTL1
SCHEMBL22096017 0.77 STAT5B (0.65) STAT5BPOLBHTTALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885POLB 4594/4885HTT 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.